

When B cells break bad: development of pathogenic B cells in Sjögren's syndrome

J.H. Reed^{1,2}, G.M. Verstappen^{3,4}, M. Rischmueller⁵, V.L. Bryant^{4,6,7}

¹The Garvan Institute of Medical Research, Darlinghurst, Australia;

²St. Vincent's Clinical School, Faculty of Medicine, UNSW Sydney, Australia;

³Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, the Netherlands;

⁴Immunology Division, Walter and Eliza Hall Institute for Medical Research, Parkville, Australia;

⁵Rheumatology Department, The Queen Elizabeth Hospital and Discipline of Medicine, University of Adelaide, Woodville South, Australia;

⁶Department of Medicine, The University of Melbourne and Department of Clinical Immunology and Allergy, The Royal Melbourne Hospital, Parkville, Australia;

⁷Department of Clinical Immunology and Allergy, The Royal Melbourne Hospital, Parkville, Australia.

Joanne H. Reed*, PhD

Gweny M. Verstappen*, PhD

Maureen Rischmueller, MBBS, FRACP

Vanessa L. Bryant, PhD

*These authors contributed equally.

Please send correspondence to:

Joanne H. Reed,

Garvan Institute of Medical Research,
384 Victoria Street,

Darlinghurst, NSW 2010, Australia.

E-mail: j.reed@garvan.org.au

Received on July 2, 2020; accepted in revised form on July 29, 2020.

Clin Exp Rheumatol 2020; 38 (Suppl. 126): S271-S282.

© Copyright CLINICAL AND

EXPERIMENTAL RHEUMATOLOGY 2020.

Key words: autoimmunity, Sjögren's syndrome, B cells, precision medicine

Funding: page S279.

Competing interests: M. Rischmueller has been a site Principle Investigator on clinical trials in primary Sjögren's syndrome for BMS and Novartis. The other authors have declared no competing interests.

ABSTRACT

Primary Sjögren's syndrome (pSS) is often considered a B cell-mediated disease, yet the precise role of B cells in the pathogenesis is not fully understood. This is exemplified by the failure of multiple clinical trials directed at B cell depletion or inhibition. To date, most prognostic markers for severe disease outcomes are autoantibodies, but the underlying mechanisms by which B cells drive diverse disease presentations in pSS likely extend beyond autoantibody production. Here we outline an expanded role of B cells in disease pathogenesis drawing on examples from animal models of SS, and from other autoimmune diseases that share similar clinical or immunological abnormalities. We focus on recent findings from the detailed analysis of pathogenic B cells in patients with pSS to propose strategies for patient stratification to improve clinical trial outcomes. We conclude that an integrated cellular, molecular and genetic analysis of patients with pSS will reveal the underlying pathogenic mechanisms and guide precision medicine.

Introduction

Primary Sjögren's syndrome (pSS) is a chronic inflammatory autoimmune disease predominantly affecting the salivary and lachrymal glands. The presence of autoantibodies and hypergammaglobulinaemia have led to pSS been considered a B cell-mediated disease. However, the majority of clinical trials testing B cell targeted therapies in pSS, have failed to meet primary endpoints for clinical improvement, indicating the precise role of B cells in disease pathogenesis is not yet completely understood. Compounding clinical trial failure is the heterogeneity of clinical phenotype in patients with pSS, mani-

festing as three major stages. Stage 1 is characterised by autoimmune exocrinopathy with dry eyes and mouth, fatigue, arthralgia, and the presence of serum autoantibodies in >80% of patients, particularly IgG targeting SSA/Ro and SSB/La ribonucleoproteins and IgM rheumatoid factors (1). These autoantibodies are present a median of more than four years before Stage 1 clinical signs (2) (Fig. 1). Disease management of Stage 1 is mainly composed of symptomatic treatment (e.g. artificial tears and saliva, NSAIDs) as disease-modifying treatment options are lacking. Approximately 30–40% of patients progress to stage 2, which is defined by increased disease severity with at least one additional systemic autoimmune manifestation, which may involve the skin, lungs, muscle, kidney, heart, gastrointestinal, central and peripheral nervous systems, and haemopoietic system (3). Systemic autoimmune complications are mediated by immune complex deposition (e.g. cryoglobulinaemic-associated vasculitis and glomerulonephritis) and/or inflammatory cell infiltration of organs and tissues (e.g. interstitial nephritis, constrictive bronchiolitis, interstitial lung disease). Histological examination of affected organs, including the salivary glands, reveal that B cells are a key constituent of the cellular infiltrate (Fig. 2). However, the significance of infiltrating B cells at sites of organ damage in pSS is poorly understood, and there is ongoing debate around whether these hyperactivated B cells are direct initiators of disease pathogenesis or bystanders responding to an inflammatory environment. The latter is, however, unlikely, since the third stage of pSS is progressive development of monoclonal B cell lymphoproliferative disease, most commonly salivary gland mucosa-associated lymphoid tissue (MALT)

lymphomas. B cell malignancies arise in approximately 5% of patients with pSS (4) representing a 20-fold increased risk of lymphoma compared to the general population (3) and the highest risk among individuals affected by all autoimmune diseases (4). There is an increase in non-Hodgkin lymphoma-specific mortality in pSS (standardised mortality ratio 3.25) (5). Rheumatoid factor autoantibodies are closely associated with progression to stage 3 with cryoprecipitable rheumatoid factors being an independent predictor of lymphoma in pSS (6). Moreover, the majority of salivary gland MALT lymphomas express surface IgM comprising stereotypic immunoglobulin rearrangements with rheumatoid factor autoantibody specificity (7). Hence, autoreactive B cells not only contribute to disease progression via production of autoantibodies, but may also become pathogenic through uncontrolled clonal expansion. Multiple B cell intrinsic and extrinsic factors can contribute to this uncontrolled B cell expansion, including polymorphic loci in genes that affect B cell biology (8). In addition to autoantibody production and lymphomagenesis, B cells can contribute to pathogenesis by antigen presentation and pro-inflammatory cytokine production (Fig. 1).

Given the multi-faceted role of B cells in pSS it is likely that therapies directly targeting B cells at various developmental and functional stages and by various pathways, will be required for effective treatment. The aim of this review is to examine the development and function of pathogenic B cells in pSS by evaluating animal and clinical models of pSS and other autoimmune diseases with a focus on recent analysis of pathogenic B cells from patients with pSS. We review potential factors that may contribute to poor clinical trial outcomes and provide a pathway towards precision medicine with a patient vignette and model for patient stratification.

B cell mediated pathology in pSS

Direct contributions of B cells to pathogenesis

• *Autoantibodies*

Serum autoantibodies provide substantive evidence for autoimmune-mediated

exocrine gland pathology in pSS. Anti-52kD SSA/Ro (Ro52) and anti-60kD SSA/Ro (Ro60) autoantibodies are most common in pSS and hence one of the key objective criteria for diagnosis (9). Other common autoantibodies in pSS include anti-SSB/La and rheumatoid factor. While anti-Ro/La and rheumatoid factor autoantibodies occur in a majority of patients, they are not exclusive to pSS and can occur in individuals with other autoimmune diseases. Likewise, many autoantibodies associated with other systemic autoimmune diseases are also found in pSS, such as anti-centromere, anti-cyclic citrullinated peptides, anti-mitochondrial and anti-DNA antibodies (10). In addition, a range of autoantibodies not routinely tested in diagnostic laboratories have been detected in patients with pSS, including anti-M3 muscarinic acetylcholine receptors (M3R), anti-alpha-fodrin, anti-salivary gland protein 1, anti-carbonic anhydrase 6 and anti-parotid secretory protein antibodies. The incidence and clinical significance of these minor autoantibodies has been previously reviewed (10).

The presence and increased titres of anti-Ro, anti-La and rheumatoid factor serum autoantibodies are correlated with more severe disease in patients with pSS (11). However, the occurrence of these same autoantibodies in asymptomatic individuals years prior to developing clinical signs of disease, poses questions about their pathogenicity (2, 12). Anti-Ro52 and anti-Ro60 autoantibodies are almost universally implicated in neonatal lupus, a passively acquired autoimmune syndrome manifesting as a transient rash, cytopenia, mild hepatic derangement, or congenital heart block (13); and are also strongly associated with subacute cutaneous lupus erythematosus in adults with pSS, systemic lupus erythematosus (SLE), or isolated cutaneous lupus erythematosus (14). Only 2% of anti-Ro positive mothers give birth to a child with neonatal lupus, however the risk in later pregnancies following an affected neonate rises to 17% (15), suggesting that specific attributes define pathogenic autoantibodies, such as epitope specificity, and/or other factors

such as foetal microenvironment and genetics may contribute to autoantibody pathogenicity (16-20). Interestingly, neonatal lupus overwhelmingly occurs in offspring of asymptomatic women, 30% of whom later develop pSS (21), possibly related to the increased prevalence of pSS in relation to SLE (both diseases exhibiting anti-Ro antibodies), the frequently delayed and older age at diagnosis of pSS, and disease-specific differences between these antibodies (22-24) – an important area for future research.

Rheumatoid factor autoantibodies targeting IgG Fc present a similar scenario: seemingly benign autoantibodies are detected in a majority of patients, but are directly linked to the development of severe autoimmune pathology caused by type II mixed cryoglobulinaemia, in only a few. Type II mixed cryoglobulinaemia most often presents as glomerulonephritis and cutaneous vasculitis, caused by deposition of immune complexes composed of IgM rheumatoid factor and polyclonal IgG precipitating at low ambient temperatures in small to medium sized blood vessels. The pathogenicity of rheumatoid factors in complex with IgG is well-established and was first demonstrated in passive transfer to rodents, to cause cutaneous vasculitis where lower temperature is a co-factor or glomerulonephritis when undefined co-factors trigger precipitation in the mesangium (25-28).

Evidence for an expanded role of B cells in pSS pathogenesis beyond production of autoantibodies comes from clinical trials with the chimeric anti-CD20 monoclonal antibody rituximab. Rituximab results in almost complete depletion of CD20-expressing B cells (including naïve and memory B cell compartments) and short-lived plasmablasts in both the periphery and salivary glands, reduced numbers of T follicular helper cells and has a variable effect on long-lived plasma cells, which typically have low expression of CD20 (29). Clinical efficacy of open-label rituximab measured by decreased ESSDAI score and increased salivary flow was achieved in the presence of sustained anti-Ro/La autoantibody titres (30), suggesting an expanded role for B cells




Fig. 1. Proposed development and function of pathogenic B cells during Sjögren's syndrome disease progression.

Multiple germline and somatic variants in immune regulatory genes (IRG) enable B cells bearing stereotypic, autoreactive B cell receptors to evade tolerance pathways, survive, proliferate and differentiate into autoantibody secreting cells. Autoreactive B cell hyperactivation, antibody variable region (VDJ) mutation and autoantibody secretion can occur via T cell independent or dependent pathways. For T cell-independent activation, self-antigens associated with nucleic acids (e.g. Ro ribonucleoproteins) provide a dual signal, stimulating the B cell receptor (BCR) and ligating endosomal Toll-like receptors (TLR). For T cell-dependent activation, autoreactive B cells present autoantigen via MHC Class II to CD4⁺ helper T cells resulting in differentiation into T effector populations including T follicular helper cells that promote antibody somatic hypermutations to enhance autoantibody affinity. Secreted autoantibodies form pathogenic immune complexes with autoantigens that stimulate additional inflammatory signalling including TLR activation and Type I interferon. Chronic self-antigen stimulation, inflammatory microenvironment and accumulating somatic mutations provide the necessary conditions for uncontrolled proliferation of autoreactive B cells leading to clonal expansion and lymphoma.

in disease pathogenesis. Inconsistencies in clinical efficacy for rituximab reported in different trials (31-33) supports a hypothesis where B cells at different developmental stages, in different microenvironments, contribute to the broad clinical phenotypes observed across patients with pSS and unpredictable responses to treatment. Hence, understanding how B cells contribute to disease pathogenesis and specifically how and where pathogenic B cells develop and differentiate is imperative to successful B cell targeting.

• Antigen presentation

A beneficial clinical response to rituximab has also been reported in patients with autoimmune diseases where the pathogenesis was originally thought to be T-cell mediated or not caused by autoantibodies: multiple sclerosis (34) and type I diabetes (35). Findings from both the non-obese diabetic (NOD) mouse model of diabetes and experimental autoimmune encephalitis (EAE) model of multiple sclerosis demonstrated that

B cells, but not secreted autoantibody, are essential for disease development (36, 37). In these models, B cells initiate disease via MHC class II restricted antigen presentation, as deficiency in class II molecules on B cells, but not other antigen presenting cells, prevented CD4⁺ T cell activation and diabetes in NOD mice (38). Similarly, selective deletion of MHC Class II on B cells rendered mice resistant to EAE due to a B cell dependent block in T_H1 and T_H17 development (37). More recent experiments evaluating human B cells *ex vivo* obtained from patients with multiple sclerosis support these findings by demonstrating that antigen experienced memory B cells directly stimulate proliferation and activation of CD4⁺ T cells (39). Likewise, transglutaminase 2 specific B cells from patients with coeliac disease showed a dominant antibody response to an N-terminal epitope that coincided with antigen presentation to CD4⁺ T cells and disease onset (40). The main genetic risk associations for pSS are in genes assigned to antigen

presentation pathways, particularly the human leukocyte antigen-DR and -DQ isotypes that are positively associated with disease pathogenesis and control the diversification of the Ro/La autoantibody response (41). It would be interesting to determine whether the approximate 20% of patients with pSS that are "serologically negative" (e.g. lacking anti-Ro/La autoantibodies) and diagnosed by lymphocytic infiltrates in salivary gland biopsies show a clinical response to B cell targeted therapies. Often this sub-group of patients are excluded from clinical trials targeting B cells as their disease pathogenesis is considered to be B cell-independent or do not constitute a large enough sample size for correlations to be made. However, it is tempting to speculate that B cells infiltrating the salivary glands mediate pathogenesis by presenting autoantigens to T cells and promoting inflammation in a similar manner to pathogenic B cells in multiple sclerosis and type I diabetes. Further research, in animal models of pSS and clinical

disease is needed to determine whether autoreactive B cells function as antigen presenting cells to activate autoreactive T cells in pSS.

• Cytokine production

A third potential mechanism of B cell pathogenicity in pSS is via endogenous secretion of pro-inflammatory cytokines. In particular, Toll-like receptor (TLR)-activated B cells express a variety of pro-inflammatory (*e.g.* IL-6, TNF- α) and anti-inflammatory (*e.g.* IL-10) cytokines (42). A potential role of B cells as a major source of pro-inflammatory cytokines is reinforced by the observed decline in serum IL-6 levels following B cell depletion therapy with rituximab in pSS patients (43). Moreover, in the EAE mouse model of multiple sclerosis, a B cell-specific IL-6 deficiency reduced disease severity and rituximab treatment ameliorated disease only in mice with IL-6-sufficient B cells at baseline (44). While IL-6-producing B cells may be actively involved, numbers and/or suppressive function of IL-10-producing (regulatory) B cells are often decreased in autoimmune conditions (45). However, current evidence indicates no functional impairment of IL-10-producing B cells in pSS (46). In addition to IL-10, B cells can exert regulatory function via production of IL-35 (IL-12p35/Ebi3) (47). Interestingly, serum levels of IL-35 were decreased in pSS patients and IL-12p35 and Ebi3 mRNA transcripts in blood were detected only in B cells, suggesting that B cells in pSS produce lower amounts of IL-35 (48). Whether this can be directly translated to B cells in the target organs of pSS remains to be investigated, but it is plausible that a disturbed balance between pro- and anti-inflammatory B cell-derived cytokines contributes to the ongoing inflammation in these organs.

Factors contributing to B cell hyperactivity

• Genetic risk factors contributing to enhanced B cell activation

In addition to HLA type II polymorphisms, multiple risk loci for pSS have been established in genes involved in B cell response, including *BLK*, *IRF5*,

TNIP1, *STAT4* and *CXCR5*, albeit with relatively low odds ratios (49) as well as *BAFF* (with an odds ratio of 2.6) (50). A germline variant of *TNFAIP3* (A20), a negative regulator of NF- κ B signalling, was specifically linked to pSS-associated lymphoma (6) and more recently, to pSS risk in general (51). An additional contribution of genetics to disease initiation in pSS may be X chromosome dosage, since X chromosome aneuploidies are in excess among patients with pSS (52, 53). Candidate genes that mediate the X dosage effect are *TLR7* and *CXorf21*, an IFN-inducible gene of which expression correlates with *TLR7* (54). These genes participate in innate immune responses and have the ability to escape X-inactivation (55, 56). Biallelism of these (and other) genes may contribute to the strong female bias seen in euploid patients with pSS and SLE. Epistatic genetic interactions have also been defined as risk factors for pSS, such as those between HLA and the RCA alpha block (Regulators of Complement Activation), a region important for the non-inflammatory clearance of immune complexes (57). Together, the combination of multiple known and as yet undiscovered genetic polymorphisms can predispose the B cells to hyper-responsiveness.

• T-cell independent B cell activation via IFN and BAFF

TLR signalling is central to T-cell independent B cell responses and can be greatly enhanced by type I interferon (IFN) (58, 59). TLRs are not only capable of pathogen recognition, but may also recognise self-antigens, in particular nuclear antigens released from apoptotic cells. Dual engagement of the B cell receptor (BCR) and TLR signalling pathway by nuclear antigens is thought to play a central role in breaking tolerance and autoimmunity (59). For example, pSS-associated autoantigens Ro52, Ro60, and La form complexes with RNA and as such may directly engage specific TLRs (TLR3, 7, 8) expressed by B cells (60, 61). The importance of TLR signalling is further supported by the finding that in lupus-prone mice both formation of anti-nuclear antibodies and tissue infil-

tration of T cells depend on intact TLR signalling in B cells (62). Of particular interest to pSS, type I IFN specifically enhances TLR7-mediated activation of naïve B cells (63). In line with this finding, pre-incubation of naïve B cells from healthy donors with IFN- α could recapitulate the observed hypersensitivity of naïve B cells from pSS patients to TLR7, but also TLR9 agonists (64). In addition to TLR upregulation, increased expression of IFN-stimulated genes (ISGs) has been observed in blood B cells and in salivary gland tissue of a majority of patients with pSS and correlates with anti-Ro/La expression. Chronic inflammation due to TLR and type I IFN signalling may be caused or exacerbated by genetic polymorphisms in *IRF5*, a transcription factor that induces pro-inflammatory cytokines including IFN- α (65). Patients carrying the *IRF5* risk variants had increased expression of *IRF5* mRNA and type I IFN inducible genes (66). Furthermore, presence of a 'type I IFN signature' in peripheral blood is strongly associated with increased B cell activity (*e.g.* higher levels of autoantibodies); reviewed by (67). Interestingly, a recent study showed that *EPSTII1*, an ISG involved in NF- κ B pathway activation, is elevated in B cells from pSS patients (68). Thus, type I IFN broadly enhances innate signalling pathways and thereby contributes to continued B cell activation.

In addition to its direct effects on B cells, type I IFN can also indirectly influence B cells via induction of B cell activating factor (BAFF) secretion by various cell types. BAFF promotes survival of B cells at immature and mature stages of B cell development (69, 70). BAFF transgenic mice develop autoimmunity with pathologic features of both SLE and pSS (71, 72). BAFF is produced by cultured salivary gland epithelial cells (SGEC) upon stimulation with IFN and SGECs are probably a major local source of BAFF *in vivo* (73). In the salivary glands, BAFF can enhance the survival of memory B cells and plasmablasts. The involvement of BAFF in the pathogenesis of pSS in humans is illustrated by elevated systemic BAFF levels and *BAFF* gene

expression in the inflamed salivary gland tissue (72, 74, 75). Interestingly, anti-BAFF treatment with belimumab resulted in a larger decrease in serum immunoglobulin levels in pSS patients with a type I IFN 'high' versus 'low' signature (76).

In addition to sustaining B cell activation, high levels of BAFF in peripheral blood of patients with pSS may also contribute to breaches of tolerance at early stages of B cell development. This is exemplified in BAFF transgenic mice, which appear to have less stringent selection of newly emigrant/transitional B cells and subsequent survival of low affinity self-reactive B cells (72). Also, in patients with pSS, central and peripheral tolerance checkpoints seem impaired, since both newly emigrant/transitional B cells and naïve B cells harbor an increased proportion of polyreactive cells (77). Notably, patients with pSS have an expanded population of CD21^{low} B cells that are enriched for autoreactive cells. These cells respond to activation via TLRs, but not via their BCR, and can undergo clonal expansion (78, 79). In addition to BAFF, increased type-I IFN expression and the concomitant increase in ISG expression can also contribute to breaks in tolerance checkpoints. In patients with SLE, transitional B cells from untreated patients with or without flares show overexpression of ISGs and the highest IFN score was seen in early transitional cells (80). In line with this finding, resting naïve B cells from SLE patients showed epigenetic modifications in IFN-stimulated genes, indicating early-stage priming and perturbed B cell development in the bone marrow (81). Although not yet proven, similar perturbations in transitional and naïve B cells are probably involved in pSS. Interestingly, resting naïve B cells from patients with pSS further show elevated Bruton's tyrosine kinase (BTK) and CD86 expression, inclining a lower activation threshold (82). Together, (poly)genetic changes in B cells, chronic type I IFN activation and subsequent secretion of BAFF by innate immune cells and epithelial cells in pSS can promote B cell activation and survival in a T cell-independent manner.

• T-cell dependent B cell activation via IL-21

T-cell dependent activation of B cells also contributes to the development of pathogenic B cells (83). The proportion of activated T follicular helper (Tfh) cells in blood from pSS patients correlates with systemic disease activity and the frequency of Tfh cells in the inflamed salivary glands correlates with lymphocytic focus score and B cell activity parameters (84-86). Furthermore, IL-21 transcript levels are enriched in labial gland biopsies with ectopic lymphoid structures and in parotid MALT lymphoma (87). IL-21 is a potent inducer of IgG and IgA antibody secreting cell differentiation (88). Interestingly, IL-21 is also a critical cytokine for the differentiation of a pathogenic, extrafollicular B cell subset in patients with lupus nephritis. These pathogenic B cells are characterised by a CXCR5⁺CD21^{lo}CD11c^{hi}T-bet⁺ phenotype and their activation and differentiation into antibody secreting cells depends on TLR7 and IL-21 signalling (89, 90). Although not yet formally proven, pathogenic B cells with a similar phenotype are likely involved in the pathogenesis of pSS and these cells will be further discussed below.

Examples of pathogenic B cell subsets

Rogue B cells producing pathogenic cryoglobulins

Recent advances in single cell omics and mass spectrometry technologies have enabled the "rogue" B cells responsible for producing pathogenic cryoprecipitating rheumatoid factors to be identified, isolated and compared with other circulating B cells in patients with pSS complicated by type II cryoglobulinaemia (91). Rogue B cell clones in 4 patients showed immunophenotypes resembling memory B cells and plasmablasts with increased antigen presenting molecule expression (CD86, HLA) compared to polyclonal memory B cell and plasmablast counterparts from the same patient. Consistent with the pathogenic extrafollicular B cell subset in patients with lupus nephritis, CD21 expression was low; however, CD11c expression was variable. Single cell molecular analysis

of clonal rheumatoid factors enabled the construction of evolutionary trees, which revealed that pathogenic cryoglobulins arise from B cells bearing benign soluble rheumatoid factors that accumulate mutations in both lymphocyte regulatory genes and immunoglobulin V(D) J gene segments. Rogue B cells from all 4 patients carried one or multiple somatic mutations in genes found recurrently as drivers of lymphoma including *CARD11*, *TNFAIP3*, *CCND3*, *ID3*, *BTG2* and *KLHL6*. These genes normally function in regulating B cell activation, differentiation, proliferation and antibody V-region mutation. Somatic hypermutation to the antibody itself bestowed rheumatoid factor pathogenicity by increasing the propensity to form insoluble immune complexes with IgG. Further, lymphocyte regulatory gene mutations appeared to precede pathogenic antibody variable (V)-region mutations, which led to the hypothesis that lymphoma driver mutations are required to evade the tolerance checkpoints that normally prevent B cells from secreting a pathogenic autoantibody. Whether this shared pathogenic process with lymphoma is unique to B cells producing cryoprecipitating rheumatoid factors, thereby explaining the increased risk of lymphoma in pSS patients with cryoglobulinaemia, or common for other autoreactive lymphocytes remains to be established and has important implications for treating pSS and other autoimmune diseases by repurposing existing lymphoma therapies.

The accumulation of antibody V-region mutations to produce a pathogenic autoantibody appeared to be a gradual process, taking over 3 years in one patient with progressing disease from stage 1 glandular features to stage 2 type II cryoglobulinaemia. Moreover, this disease process appeared to be stochastic with one patient's cryoprecipitating rheumatoid factor accumulating additional V-region mutations that ultimately restored rheumatoid factor solubility. This gradual and stochastic process of V-region mutation altering autoantibody pathogenicity could explain the presence of autoantibodies in asymptomatic individuals, sporadic onset of symptoms and variability in disease course

over time. Previous studies that have sequenced and cloned anti-Ro52 and anti-La autoantibodies from patient peripheral blood have also indicated a central role for immunoglobulin V-region mutation in producing or enhancing auto-reactivity (92, 93). What enables the B cells producing anti-Ro/La autoantibodies to bypass tolerance checkpoints and secrete high titre, high affinity autoantibodies remains undefined. It is possible that these B cells may acquire somatic mutations in lymphoma driver genes similar to rheumatoid factor B cells. Alternatively, extrinsic changes in the inflammatory milieu that promote B cell activation and/or change the quantity, quality or specificity of autoantibody, could also contribute to the emergence of pathogenic clones.

FcRL4-expressing B cells in salivary gland tissue

Advanced stages of salivary gland disease in pSS are characterised by an increase in infiltrating B cells (Fig. 2A) and differentiated plasma cells (94). A characteristic histopathologic feature of pSS involving B cells is the formation of lympho-epithelial lesions (LELs). LELs consist of proliferative intraepithelial B cells and hyperplastic ductal epithelium, with the influx of intraepithelial B cells a likely first step in LEL formation (95). Importantly, the development of MALT lymphoma ('stage 3' of pSS) is strongly associated with the presence of LELs (96). Below, we discuss the potential pathogenic role of a FcRL4-expressing B cell subset that is associated with LELs and MALT lymphoma in pSS.

• *Pathogenic role of tissue-based FcRL4⁺ B cells*

Fc receptor-like (FcRL) 4 is an immunoregulatory receptor expressed by a specific subset of tissue-based memory B cells (97, 98). FcRL4 is a receptor for IgA and recent findings show that it binds specifically to systemic and mucosal IgA, but not secretory IgA (sIgA; IgA attached to a secretory component) (99). Interestingly, expression and ligation of FcRL4 inhibits BCR-mediated and promotes TLR-mediated activation of B cells (100). *In vitro*, B cells up-




Fig. 2. B cell involvement and pathogenic B cells in salivary gland tissue. **A:** Immunohistochemical staining for CD20 (left) and FcRL4 (right) on parotid gland tissue sections illustrate the involvement of B cells in tissue pathology (positive staining, brown; x20 actual magnification). CD20⁺ B cells are abundantly present in periductal infiltrates and also within lympho-epithelial lesions (asterisk). FcRL4⁺ cells are predominantly found within the lesions. **B:** Proposed phenotypical differences between bystander glandular B cells and pathogenic glandular B cells that infiltrate the ductal epithelium.

regulate FcRL4 expression after stimulation with soluble CD40 ligand and/or CpG DNA, indicating that FcRL4 is also a marker of recent activation (101). However, the mechanisms involved in FcRL4⁺ B cell formation *in vivo* remain elusive.

FcRL4-expressing B cells were first linked to pSS pathogenesis in the context of MALT lymphomas, where FcRL4 was mainly expressed by tumour cells involved in LELs (102). Haacke *et al.*, showed that in addition to pSS-associated MALT lymphomas, FcRL4 is expressed by intraepithelial B cells and subepithelial B cells in inflamed salivary gland tissue of pSS patients without lymphoma (Fig. 2A) (103). This study also found that FcRL4⁺ cells are proliferating within LELs. Further characterisation of FcRL4⁺ B cells isolated from parotid gland tissue of patients with pSS showed that these cells are chronically activated,

pro-inflammatory B cells. Glandular FcRL4-expressing B cells contained, for example, higher transcript levels of genes encoding CD11c, T-bet, TACI, IL-6, and NF-κB1/p50, compared with FcRL4-negative counterparts (104). The transcriptional profile of glandular FcRL4⁺ B cells shows similarities to the double negative (CD27⁻/IgD⁻) CD11c^{hi} memory B cell subset associated with the pathogenesis of lupus nephritis (89) (Fig. 2B). However, in contrast to CD11c^{hi} B cells in lupus, glandular FcRL4⁺ B cells do not express markers associated with antibody-secreting cells, such as IRF4 or Blimp-1 (103) suggesting that FcRL4⁺ B cells contribute to pathogenesis by mechanisms other than antibody secretion. Further, the finding that FcRL4⁺ B cells are proliferating within the ducts, together with the observation that clonal expansions are present among intraductal B cells (105), suggests that FcRL4⁺ B

Table I. Clinical outcomes of randomised controlled trials with B-cell targeted therapies in primary Sjögren's syndrome.

Trial	Drug	Target	n (treatment/ placebo)	Primary outcome	Primary outcome met	Improved secondary outcomes*	Comments
Meijer <i>et al.</i> , 2010 (123)	Rituximab	CD20	20/10	SWSF (mean change from baseline)	Yes	- UWSF - Lissamin green test - VAS dryness - MFI general fatigue - SF-36	Post-hoc analyses showed improvement in ESSDAI score and SG morphology (124, 125)
Devauchelle-Pensec <i>et al.</i> , 2014 (126)	Rituximab	CD20	60/60	VAS scores week 24 (improvement of at least 30 mm in 2 of 4 VASs)	No	- VAS fatigue - VAS dryness	Post-hoc analyses showed improvements in composite endpoint and SG ultrasound score (127, 128)
Bowman <i>et al.</i> , 2017 (129)	Rituximab	CD20	67/66	VAS scores week 48 (30% reduction in either fatigue or oral dryness)	No	- UWSF	Post-hoc analysis showed improvement in SG ultrasound score (130)
Dörner <i>et al.</i> , 2020 (131)	Ianalumab	BAFF-R	190**	ESSDAI week 24 (change from baseline)	Yes	- PhGA	Endpoint was met for 300mg dose only. Second blinded treatment period ongoing

SWSF: stimulated whole salivary flow; UWSF: unstimulated whole salivary flow; VAS: Visual Analogue Scale; MFI: Multidimensional Fatigue Index; SF-36: Short Form (36) Health Survey; ESSDAI: EULAR Sjögren's syndrome disease activity index; SG: salivary gland; PhGA: physician's global assessment.

*Improvement over time compared with placebo.

**190 patients allocated 1:1:1 over placebo and three different doses of ianalumab.

cells are continuously activated by the ductal epithelium. Furthermore, expression of TACI provides a local survival mechanism for these cells, since activated salivary gland epithelial cells produce high levels of the TACI ligand BAFF (73). In turn, FcRL4⁺ B cells themselves produce cytokines, such as IL-6, that support inflammation of the epithelium. Finally, we speculate that transient expression of AID by chronically activated FcRL4⁺ B cells may result in off-target mutations (*i.e.* outside of Ig genes) and incidental acquisition or accumulation of lymphoma-driver mutations observed in cryoglobulin producing rogue B cells (91).

Avenues for targeting pathogenic B cells

Although two large randomised controlled trials (RCTs) of B cell depletion therapy using rituximab did not meet their primary endpoint in pSS, there are indications that a -yet to be stratified- subgroup of pSS patients benefit from this treatment (33). Excitingly, preliminary results of dual BAFF receptor inhibition and B cell depletion with ianalumab suggest clinical efficacy in pSS patients with moderate-to-high systemic disease activity (106). Observed clinical improvements in

RCTs with B cell targeted therapies are summarised in Table I. Other promising approaches currently under investigation are sequential treatment with belimumab (anti-BAFF) and rituximab to enhance depletion of B cells in affected tissues and inhibition of BTK, which sits at the crossroads of BCR and TLR signalling (107, 108). Of further interest, a *post-hoc* analysis of an RCT with epratuzumab (anti-CD22) in SLE patients with associated SS, suggesting a greater pathogenic role of CD22-expressing B cells in this subgroup (109). Besides the aforementioned B cell targeted approaches, drugs that block costimulatory proteins, such as anti-CD40, and more broadly acting immunosuppressive treatments, such as combined use of hydroxychloroquine and leflunomide, may affect pathogenic B cells in pSS (110-112). Furthermore, therapies that have recently shown clinical efficacy in SLE trials (*i.e.* anti-IL-12/23 p40 and anti-IFN- α receptor antibodies) may also be useful for (partial) inhibition of B cell activation (113, 114). With the availability of multiple promising new therapeutics, the challenge remains to identify responders *a priori* and to achieve this, we may need to rethink patient stratification. For

example, an elegant new approach of clinical phenotyping based on patient-reported symptoms was recently proposed by Tarn *et al.* (115). However, given the heterogeneity of pSS, it is likely that patients with similar clinical phenotypes may exhibit a range of underlying pathologies. Therefore, stratification of patient groups should also consider disease endotypes, similar to other chronic diseases. To define a 'B cell dominant' endotype, patient stratification will need to extend from autoantibody positivity alone to standardised assays to measure hyper-responsiveness of B cells, phenotypical and functional markers to define pathogenic B cells, and surrogate biomarkers that reflect pathogenic B cell involvement in affected tissues as well as genomic markers of disease. Since the roles of B cells in disease pathogenesis are diverse, the specific target for treatment may need to be adjusted at the individual patient level (Fig. 3). It is unlikely that different B cell targeting therapies will be equally effective in heterogeneous groups of patients, or that a single, uniform targeted strategy will be effective as illustrated by a recent case series of pSS patients with cryoglobulinaemic vasculitis refractory to rituximab alone, but successfully treated by the com-

bination of rituximab and belimumab (anti-BAFF) (116). Below we provide an additional example that highlights the complexity and promise of molecularly defining a pathogenetic B cell response, to guide precision medicine approaches.

Patient vignette and concluding remarks

Here, we present a case vignette as an illuminating example of how understanding the role of B cells in disease pathogenesis could drive the application of precision medicine. The case was one of the 4 patients with cryoglobulinaemia found to exhibit lymphoma driver mutations, reported above (91). A 23-year-old woman was taken to the emergency department with quadriplegia, one week following an upper respiratory tract infection. The cause of her paralysis was identified as severe hypokalaemia due to distal renal tubular acidosis. Following review by a renal physician with an interest in pSS, the cause was determined as tubulointerstitial nephritis secondary to stage 2 pSS. In fact, the patient had presented to her primary physician 6 years earlier at the age of 17, in stage 1 pSS with severe fatigue, salivary glandular swelling and sicca symptoms, but was diagnosed only with depression. Her disease progressed over the following decade, manifesting as severe sicca symptoms, inflammatory polyarthritis, ongoing type I distal renal tubular acidosis complicated by nephrocalcinosis and frequent hospital admissions with urosepsis; despite treatments including hydroxychloroquine, corticosteroids, methotrexate and mycophenolate mofetil. Serum parameters revealed high rheumatoid factor, low C3 and C4, hypergammaglobulinaemia, IgA kappa and IgM kappa paraproteins, and type II mixed cryoglobulinaemia. Cyclophosphamide, and plasmapheresis were used sequentially to treat cryoglobulinaemic vasculitis, which manifest with cutaneous and gallbladder vasculitis, and bilateral ulnar nerve palsy. Several courses of rituximab, given as 2 doses of 1 g infusions two weeks apart, led to minimal improvement in clinical symptoms or serum cryoglobulin levels. Sin-




Fig. 3. Model for precision medicine with proposed B cell-targeted therapies in Sjögren's syndrome. Four aspects of B cell biology and conforming treatment options are displayed. We hypothesize that each patient has an individual B cell activation signature and that patients may be categorised in different profiles (colours) to guide precision treatment decisions. Therapies that target B cells directly are shown in blue and therapies that target B cells indirectly are shown in grey. More broadly acting, immunomodulatory drugs such as hydroxychloroquine and leflunomide are not displayed, but can also target B cells. Additional therapies that have recently shown clinical efficacy in systemic lupus erythematosus trials (*i.e.* anti-IL-12/23 p40 or anti-IFN- α receptor antibodies) may also be useful for inhibition of B cell activation.

gle cell analysis revealed a plausible explanation for the failure of rituximab in this patient: the majority of her B cells producing the pathogenic cryoglobulin had differentiated into plasmablasts with very low to no surface CD20. These rogue clones represented more than one third of the patient's CD27⁺ memory B cell and plasmablast compartment 3 months after treatment with rituximab. The cryoglobulin-producing B cells also carried a *CARD11* mutation at a site frequently mutated in diffuse large B cell lymphoma causing hyperactivation of inflammatory mediator NF- κ B and differentiation into plasmablasts (91, 117). While the combined cellular, molecular and genetic analysis of B cells producing pathogenic autoantibody, as outlined here, is important to understand disease pathogenesis, it also provides insight into treatment selection. BTK inhibitors such as ibrutinib are a lym-

phoma treatment that has recently entered clinical trials for pSS. Importantly, lymphomas carrying *CARD11* gain-of-function mutations are resistant to treatment with ibrutinib because the *CARD11* mutation causes a constitutively active *CARD11* downstream of BTK, which activates NF- κ B independent of BCR signalling and BTK (118). Therefore, ibrutinib would not perturb the pathogenic cryoglobulin producing B cells in this patient and should be avoided. Along similar lines, comes the great anticipation that detailed analyses of pathogenic B cells will identify novel therapeutic targets and pathways. One of the most differentially expressed genes in this patient's rogue cells compared to her developmentally matched polyclonal B cells was *CD86*, which encodes a surface protein that interacts with CD28 on T cells to stimulate immune responses. Previous studies in mice have shown that overexpression

of CD86 on self-reactive B cells is sufficient to evade a tolerance checkpoint of T cell-mediated apoptosis and instead receive T cell help to drive autoantibody secretion (119). Abatacept, a CTLA4-Ig fusion protein registered for the treatment of rheumatoid arthritis, blocks CD86-CD28 interaction and may provide an avenue for eliminating these rogue B cells. However, as with most other trials of biologic therapies for pSS (120), abatacept failed to meet its primary endpoints in two phase 3 randomised controlled trials (112, 121), possibly due to inadequate stratification of clinical trial subjects with respect to pathologic B cell phenotypes. The challenge moving forward is to develop personalised treatment strategies for patients with pSS via stratification according to the pathogenic mechanisms governing their various clinical manifestations (122). This will require the development of technology to apply a detailed cellular and molecular genomics-based analysis to pathogenic B cells in more patients to link pathophysiological mechanisms of disease with immune function, and realise the potential of precision medicine. The development of new cellular, molecular and genetic biomarkers will better determine the efficacy of treatments for individual subjects in clinical trials and, importantly, will identify those most at risk of developing progressive disease, allow early rationalised interventions, and prevent complications of undertreated disease including progression to stage 3 pSS.

Acknowledgements

We wish to thank the patients globally who have generously contributed their personal data and blood and tissue samples, to further research into the pathogenesis of primary Sjögren's syndrome, with particular thanks to the patient included in the featured vignette with generous permission. We kindly thank E.A. Haacke and M.S. van Ginckel for providing histological slides for inclusion in Figure 2.

Funding

The figures were created with support from BioRender.com. J.H. Reed is

supported by a NSW Health early-to-mid-career Fellowship, the Rebecca L Cooper Medical Research Foundation and NHMRC Project Grant 1142186; V.L. Bryant is supported by Sir Clive McPherson Family Centenary Fellowship, DW Kier Fellowship, Holmes Grant Charitable Trust, Rae Foundation and MJ Maughan Foundation.

References

1. FOX RI: Sjögren's syndrome. *Lancet* 2005; 366: 321-31.
2. THEANDER E, JONSSON R, SJOSTROM B, BROKSTAD K, OLSSON P, HENRIKSSON G: Prediction of Sjögren's syndrome years before diagnosis and identification of patients with early onset and severe disease course by autoantibody profiling. *Arthritis Rheum* 2015; 67: 2427-36.
3. MARIETTE X, CRISWELL LA: Primary Sjögren's syndrome. *N Engl J Med* 2018; 378: 931-9.
4. KOVACS L, SZODORAY P, KISS E: Secondary tumours in Sjögren's syndrome. *Autoimmun Rev* 2010; 9: 203-6.
5. VOULGARELIS M, ZIAKAS PD, PAPAGEORGIOU A, BAIMPA E, TZIOUFAS AG, MOUTSOPOULOS HM: Prognosis and outcome of non-Hodgkin lymphoma in primary Sjögren syndrome. *Medicine* (Baltimore) 2012; 91: 1-9.
6. NOCTURNE G, VIRONE A, NG WF *et al.*: Rheumatoid factor and disease activity are independent predictors of lymphoma in primary Sjögren's syndrome. *Arthritis Rheum* 2016; 68: 977-85.
7. BENDE RJ, AARTS WM, RIEDL RG, DE JONG D, PALS ST, VAN NOESEL CJ: Among B cell non-Hodgkin's lymphomas, MALT lymphomas express a unique antibody repertoire with frequent rheumatoid factor reactivity. *J Exp Med* 2005; 201: 1229-41.
8. REKSTEN TR, LESSARD CJ, SIVILS KL: Genetics in Sjögren syndrome. *Rheum Dis Clin North Am* 2016; 42: 435-47.
9. SHIBOSKI CH, SHIBOSKI SC, SEROR R *et al.*: 2016 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Primary Sjögren's Syndrome: a consensus and data-driven methodology involving three international patient cohorts. *Arthritis Rheum* 2017; 69: 35-45.
10. FAYYAZ A, KURIEN BT, SCOFIELD RH: Autoantibodies in Sjögren's syndrome. *Rheum Dis Clin North Am* 2016; 42: 419-34.
11. RETAMOZO S, ACAR-DENIZLI N, RASMUSSEN A *et al.*: Systemic manifestations of primary Sjögren's syndrome out of the ESDAI classification: prevalence and clinical relevance in a large international, multi-ethnic cohort of patients. *Clin Exp Rheumatol* 2019; 37 (Suppl. 118): S97-106.
12. ARBUCKLE MR, MCCLAIN MT, RUBERTONE MV *et al.*: Development of autoantibodies before the clinical onset of systemic lupus erythematosus. *N Engl J Med* 2003; 349: 1526-33.
13. BUYON JP, FRIEDMAN DM: Neonatal Lupus. *In*: LAHITA RG, TSOKOS G, BUYON JP, KOIKE T (Eds.): *Systemic Lupus Erythematosus*. 5 Ed, San Diego, Academic Press 2011: 541-67.
14. MCCAULIFFE DP: Cutaneous diseases in adults associated with anti-Ro/SS-A autoantibody production. *Lupus* 1997; 6: 158-66.
15. LLANOS C, IZMIRLY PM, KATHOLI M *et al.*: Recurrence rates of cardiac manifestations associated with neonatal lupus and maternal/fetal risk factors. *Arthritis Rheum* 2009; 60: 3091-7.
16. REED JH, GIANNAKOPOULOS B, JACKSON MW, KRILIS SA, GORDON TP: Ro60 functions as a receptor for beta2-glycoprotein I on apoptotic cells. *Arthritis Rheum* 2009; 60: 860-9.
17. CLANCY RM, MARKHAM AJ, REED JH, BLUMENBERG M, HALUSHKA MK, BUYON JP: Targeting downstream transcription factors and epigenetic modifications following Toll-like receptor 7/8 ligation to forestall tissue injury in anti-Ro60 associated heart block. *J Autoimmun* 2016; 67: 36-45.
18. CLANCY RM, MARION MC, KAUFMAN KM *et al.*: Identification of candidate loci at 6p21 and 21q22 in a genome-wide association study of cardiac manifestations of neonatal lupus. *Arthritis Rheum* 2010; 62: 3415-24.
19. REED JH, CLANCY RM, PURCELL AW, KIM MY, GORDON TP, BUYON JP: β 2-glycoprotein I and protection from anti-SSA/Ro60-associated cardiac manifestations of neonatal lupus. *J Immunol* 2011; 187: 520-6.
20. STRANDBERG LS, AMBROSI A, JAGODIC M *et al.*: Maternal MHC regulates generation of pathogenic antibodies and fetal MHC-encoded genes determine susceptibility in congenital heart block. *J Immunol* 2010; 185: 3574-82.
21. RIVERA TL, IZMIRLY PM, BIRNBAUM BK *et al.*: Disease progression in mothers of children enrolled in the Research Registry for Neonatal Lupus. *Ann Rheum Dis* 2009; 68: 828-35.
22. REED JH, JACKSON MW, GORDON TP: A B cell epitope of Ro60 in systemic lupus erythematosus. *Arthritis Rheum* 2008; 58: 1125-9.
23. STRANDBERG L, WINQVIST O, SONESSON S *et al.*: Antibodies to amino acid 200-239 (p200) of Ro52 as serological markers for the risk of developing congenital heart block. *Clin Exp Immunol* 2008; 154: 30-7.
24. REED JH, DUDEK NL, OSBORNE SE *et al.*: Reactivity with dichotomous determinants of Ro60 stratifies autoantibody responses in lupus and primary Sjögren's syndrome. *Arthritis Rheum* 2010; 62: 1448-56.
25. MCCORMICK JN, DAY J, MORRIS CJ, HILL AG: The potentiating effect of rheumatoid arthritis serum in the immediate phase of nephrotic nephritis. *Clin Exp Immunol* 1969; 4: 17-28.
26. FORD PM, KOSATAKA I: The effect of human IgM rheumatoid factor on renal glomerular immune complex deposition in passive serum sickness in the mouse. *Immunology* 1982; 46: 761-8.
27. FORNASIERI A, LI M, ARMELLONI S *et al.*: Glomerulonephritis induced by human Ig-

- MK-IgG cryoglobulins in mice. *Lab Invest* 1993; 69: 531-40.
28. FORNASIERI A, TAZZARI S, LI M *et al.*: Electron microscopy study of genesis and dynamics of immunodeposition in IgMk-IgG cryoglobulin-induced glomerulonephritis in mice. *Am J Kidney Dis* 1998; 31: 435-42.
 29. VERSTAPPEN GM, KROESE FG, MEINERS PM *et al.*: B cell depletion therapy normalizes circulating follicular Th cells in primary sjögren syndrome. *J Rheumatol* 2017; 44: 49-58.
 30. CARUBBI F, CIPRIANI P, MARRELLI A *et al.*: Efficacy and safety of rituximab treatment in early primary Sjögren's syndrome: a prospective, multi-center, follow-up study. *Arthritis Res Ther* 2013; 15: R172.
 31. VERSTAPPEN GM, VAN NIMWEGEN JF, VISSINK A, KROESE FGM, BOOTSMA H: The value of rituximab treatment in primary Sjögren's syndrome. *Clin Immunol* 2017; 182: 62-71.
 32. GRIGORIADOU S, CHOWDHURY F, PONTARINI E, TAPPUNI A, BOWMAN SJ, BOMBARDIERI M: B cell depletion with rituximab in the treatment of primary Sjögren's syndrome: what have we learnt? *Clin Exp Rheumatol* 2019; 37 (Suppl. 118): S217-24.
 33. BOOTSMA H, KROESE FGM, VISSINK A: Editorial: Rituximab in the treatment of Sjögren's syndrome: is it the right or wrong drug? *Arthritis Rheum* 2017; 69: 1346-9.
 34. HAUSER SL, WAUBANT E, ARNOLD DL *et al.*: B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. *N Engl J Med* 2008; 358: 676-88.
 35. PESCOVITZ MD, GREENBAUM CJ, KRAUSE-STEINRAUF H *et al.*: Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. *N Engl J Med* 2009; 361: 2143-52.
 36. WONG FS, WEN L, TANG M *et al.*: Investigation of the role of B-cells in type 1 diabetes in the NOD mouse. *Diabetes* 2004; 53: 2581-7.
 37. MOLNARFI N, SCHULZE-TOPPHOFF U, WEBER MS *et al.*: MHC class II-dependent B cell APC function is required for induction of CNS autoimmunity independent of myelin-specific antibodies. *J Exp Med* 2013; 210: 2921-37.
 38. NOORCHASHM H, LIEU YK, NOORCHASHM N *et al.*: I-Ag7-mediated antigen presentation by B lymphocytes is critical in overcoming a checkpoint in T cell tolerance to islet beta cells of nonobese diabetic mice. *J Immunol* 1999; 163: 743-50.
 39. JELCIC I, AL NIMER F, WANG J *et al.*: Memory B cells activate brain-homing, autoreactive CD4⁺ T cells in multiple sclerosis. *Cell* 2018; 175: 85-100 e23.
 40. IVERSEN R, ROY B, STAMNAES J *et al.*: Efficient T cell-B cell collaboration guides autoantibody epitope bias and onset of celiac disease. *Proc Natl Acad Sci USA* 2019; 116: 15134-39.
 41. RISCHMUELLER M, LESTER S, CHEN Z *et al.*: HLA class II phenotype controls diversification of the autoantibody response in primary Sjögren's syndrome (pSS). *Clin Exp Immunol* 1998; 111: 365-71.
 42. LAMPROPOULOU V, HOEHLIG K, ROCH T *et al.*: TLR-activated B cells suppress T cell-mediated autoimmunity. *J Immunol* 2008; 180: 4763-73.
 43. POLLARD RP, ABDULAHAD WH, BOOTSMA H *et al.*: Predominantly proinflammatory cytokines decrease after B cell depletion therapy in patients with primary Sjögren's syndrome. *Ann Rheum Dis* 2013; 72: 2048-50.
 44. BARR TA, SHEN P, BROWN S *et al.*: B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells. *J Exp Med* 2012; 209: 1001-10.
 45. LUND FE, RANDALL TD: Effector and regulatory B cells: modulators of CD4⁺ T cell immunity. *Nat Rev Immunol* 2010; 10: 236-47.
 46. BLAIR PA, NORENA LY, FLORES-BORJA F *et al.*: CD19⁺CD24^{hi}CD38^{hi} B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients. *Immunity* 2010; 32: 129-40.
 47. SHEN P, ROCH T, LAMPROPOULOU V *et al.*: IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases. *Nature* 2014; 507: 366-70.
 48. FOGEL O, RIVIERE E, SEROR R *et al.*: Role of the IL-12/IL-35 balance in patients with Sjögren syndrome. *J Allergy Clin Immunol* 2018; 142: 258-68 e5.
 49. LESSARD CJ, LI H, ADRIANTO I *et al.*: Variants at multiple loci implicated in both innate and adaptive immune responses are associated with Sjögren's syndrome. *Nat Genet* 2013; 45: 1284-92.
 50. NOSSENT JC, LESTER S, ZAHRA D, MACKAY CR, RISCHMUELLER M: Polymorphism in the 5' regulatory region of the B-lymphocyte activating factor gene is associated with the Ro/La autoantibody response and serum BAFF levels in primary Sjögren's syndrome. *Rheumatology (Oxford)* 2008; 47: 1311-6.
 51. KHATRI B, REKSTEN TR, TESSNEER KL *et al.*: Genome-wide association study of Sjögren's syndrome identifies ten new risk loci. *Ann Rheum Dis* 2020; 79 (Suppl. 1): 30-1.
 52. HARRIS VM, SHARMA R, CAVETT J *et al.*: Klinefelter's syndrome (47,XXY) is in excess among men with Sjögren's syndrome. *Clin Immunol* 2016; 168: 25-9.
 53. SHARMA R, HARRIS VM, CAVETT J *et al.*: Rare X chromosome abnormalities in systemic lupus erythematosus and Sjögren's syndrome. *Arthritis Rheum* 2017; 69: 2187-92.
 54. ODHAMS CA, ROBERTS AL, VESTER SK *et al.*: Interferon inducible X-linked gene CXorf21 may contribute to sexual dimorphism in systemic lupus erythematosus. *Nat Commun* 2019; 10: 2164.
 55. HARRIS VM, KOELSCH KA, KURIEN BT *et al.*: Characterization of cxorf21 provides molecular insight into female-bias immune response in SLE pathogenesis. *Frontiers Immunol* 2019; 10: 2160.
 56. SOUYRIS M, CENAC C, AZAR P *et al.*: TLR7 escapes X chromosome inactivation in immune cells. *Science Immunol* 2018; 3.
 57. LESTER S, MCLURE C, WILLIAMSON J, BARDY P, RISCHMUELLER M, DAWKINS RL: Epistasis between the MHC and the RCA alpha block in primary Sjögren syndrome. *Ann Rheum Dis* 2008; 67: 849-54.
 58. SHLOMCHIK MJ: Activating systemic autoimmunity: B's, T's, and tolls. *Curr Opin Immunol* 2009; 21: 626-33.
 59. RAWLINGS DJ, SCHWARTZ MA, JACKSON SW, MEYER-BAHLBURG A: Integration of B cell responses through Toll-like receptors and antigen receptors. *Nat Rev Immunol* 2012; 12: 282-94.
 60. VOLLMER J, TLUK S, SCHMITZ C *et al.*: Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8. *J Exp Med* 2005; 202: 1575-85.
 61. REED JH, GORDON TP: Autoimmunity: Ro60-associated RNA takes its toll on disease pathogenesis. *Nature Rev Rheum* 2016; 12: 136-8.
 62. TEICHMANN LL, SCHENTEN D, MEDZHITOV R, KASHGARIAN M, SHLOMCHIK MJ: Signals via the adaptor MyD88 in B cells and DCs make distinct and synergistic contributions to immune activation and tissue damage in lupus. *Immunity* 2013; 38: 528-40.
 63. BEKEREDJIAN-DING IB, WAGNER M, HORNUNG V *et al.*: Plasmacytoid dendritic cells control TLR7 sensitivity of naive B cells via type I IFN. *J Immunol* 2005; 174: 4043-50.
 64. BRAUNER S, FOLKERSEN L, KVARNSTROM M *et al.*: H1N1 vaccination in Sjögren's syndrome triggers polyclonal B cell activation and promotes autoantibody production. *Ann Rheum Dis* 2017; 76: 1755-63.
 65. NORDMARK G, KRISTJANSDOTTIR G, THEANDER E *et al.*: Additive effects of the major risk alleles of IRF5 and STAT4 in primary Sjögren's syndrome. *Genes Immun* 2009; 10: 68-76.
 66. MICELI-RICHARD C, GESTERMANN N, ITTAH M *et al.*: The CGGGG insertion/deletion polymorphism of the IRF5 promoter is a strong risk factor for primary Sjögren's syndrome. *Arthritis Rheum* 2009; 60: 1991-7.
 67. BODEWES ILA, BJORK A, VERSNEL MA, WAHREN-HERLENIUS M: Innate immunity and interferons in the pathogenesis of Sjögren's syndrome. *Rheumatology (Oxford)* 2019 Feb 15 [Online ahead of print].
 68. SUN JL, ZHANG HZ, LIU SY *et al.*: Elevated EPST11 promote B cell hyperactivation through NF-kappaB signalling in patients with primary Sjögren's syndrome. *Ann Rheum Dis* 2020; 79: 518-24.
 69. BATTEN M, GROOM J, CACHERO TG *et al.*: BAFF mediates survival of peripheral immature B lymphocytes. *J Exp Med* 2000; 192: 1453-66.
 70. AVERY DT, KALLED SL, ELLYARD JI *et al.*: BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. *J Clin Invest* 2003; 112: 286-97.
 71. MACKAY F, WOODCOCK SA, LAWTON P *et al.*: Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. *J Exp Med* 1999; 190: 1697-710.
 72. GROOM J, KALLED SL, CUTLER AH *et al.*: Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome. *J Clin Invest* 2002; 109: 59-68.
 73. ITTAH M, MICELI-RICHARD C, ERIC GOT-

- TENBERG J *et al.*: B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjögren's syndrome. *Arthritis Res Ther* 2006; 8: R51.
74. POLLARD RP, ABDULAHAD WH, VISSINK A *et al.*: Serum levels of BAFF, but not APRIL, are increased after rituximab treatment in patients with primary Sjögren's syndrome: data from a placebo-controlled clinical trial. *Ann Rheum Dis* 2013; 72: 146-8.
 75. LAVIE F, MICELI-RICHARD C, QUILLARD J, ROUX S, LECLERC P, MARIETTE X: Expression of BAFF (BLyS) in T cells infiltrating labial salivary glands from patients with Sjögren's syndrome. *J Pathol* 2004; 202: 496-502.
 76. QUARTUCCIO L, MAVRAGANI CP, NEZOS A, GANDOLFO S, TZIOUFAS AG, DE VITA S: Type I interferon signature may influence the effect of belimumab on immunoglobulin levels, including rheumatoid factor in Sjögren's syndrome. *Clin Exp Rheumatol* 2017; 35: 719-20.
 77. GLAUZY S, SNG J, BANNOCK JM *et al.*: Defective early B cell tolerance checkpoints in Sjögren's syndrome patients. *Arthritis Rheum* 2017; 69: 2203-8.
 78. SAADOUN D, TERRIER B, BANNOCK J *et al.*: Expansion of autoreactive unresponsive CD21(-)low B cells in Sjögren's syndrome-associated lymphoproliferation. *Arthritis Rheum* 2013; 65: 1085-96.
 79. GLAUZY S, BOCCITTO M, BANNOCK JM *et al.*: Accumulation of antigen-driven lymphoproliferations in complement receptor 2/CD21(-)low B cells from patients with Sjögren's syndrome. *Arthritis Rheum* 2018; 70: 298-307.
 80. DIEUDONNE Y, GIES V, GUFFROY A *et al.*: Transitional B cells in quiescent SLE: An early checkpoint imprinted by IFN. *J Autoimmun* 2019; 102: 150-8.
 81. SCHARER CD, BLALOCK EL, MI T *et al.*: Epigenetic programming underpins B cell dysfunction in human SLE. *Nat Immunol* 2019; 20: 1071-82.
 82. CORNETH OBJ, VERSTAPPEN GMP, PAULISSEN SMJ *et al.*: Enhanced Bruton's tyrosine kinase activity in peripheral blood B lymphocytes from patients with autoimmune disease. *Arthritis Rheum* 2017; 69: 1313-24.
 83. VERSTAPPEN GM, KROESE FGM, BOOTSMA H: T cells in primary Sjögren's syndrome: targets for early intervention. *Rheumatology (Oxford)* 2019 Feb. 15.
 84. BLOKLAND SLM, VAN VLIET-MORET FM, HILLEN MR *et al.*: Epigenetically quantified immune cells in salivary glands of Sjögren's syndrome patients: a novel tool that detects robust correlations of T follicular helper cells with immunopathology. *Rheumatology (Oxford)* 2020; 59: 335-43.
 85. VERSTAPPEN GM, NAKSHBANDI U, MOSSEL E *et al.*: Is the T follicular regulatory: Fficular Hh1per T cell ratio in blood a biomarker for ectopic lymphoid structure formation in Sjögren's syndrome? Comment on the Article by Fonseca *et al.* *Arthritis Rheumatol* 2018; 70: 1354-5.
 86. FONSECA VR, ROMAO VC, AGUA-DOCE A *et al.*: The ratio of blood T follicular regulatory cells to T follicular helper cells marks ectopic lymphoid structure formation while activated follicular helper T cells indicate disease activity in primary Sjögren's syndrome. *Arthritis Rheumatol* 2018; 70: 774-84.
 87. PONTARINI E, MURRAY BROWN W, CROIA C *et al.*: A unique IL-21 signature characterizes lesional and circulating T-follicular helper cells in Sjögren's syndrome patients with ectopic germinal centres and MALT lymphoma. *Ann Rheum Dis* 2019; 78 (Suppl. 2): 221.
 88. BRYANT VL, MA CS, AVERY DT *et al.*: Cytokine-mediated regulation of human B cell differentiation into Ig-secreting cells: predominant role of IL-21 produced by CXCR5+ T follicular helper cells. *J Immunol* 2007; 179: 8180-90.
 89. JENKS SA, CASHMAN KS, ZUMAQUERO E *et al.*: Distinct effector B cells induced by unregulated toll-like receptor 7 contribute to pathogenic responses in systemic lupus erythematosus. *Immunity* 2018; 49: 725-39 e6.
 90. WANG S, WANG J, KUMAR V *et al.*: IL-21 drives expansion and plasma cell differentiation of autoreactive CD11c^{hi}T-bet^{hi} B cells in SLE. *Nat Commun* 2018; 9: 1758.
 91. SINGH M, JACKSON KJL, WANG JJ *et al.*: Lymphoma driver mutations in the pathogenic evolution of an iconic human autoantibody. *Cell* 2020; 180: 878-94 e19.
 92. MIETZNER B, TSUIJI M, SCHEID J *et al.*: Autoreactive IgG memory antibodies in patients with systemic lupus erythematosus arise from nonreactive and polyreactive precursors. *Proc Natl Acad Sci USA* 2008; 105: 9727-32.
 93. REED JH, GORNY MK, LI L, CARDOZO T, BUYON JP, CLANCY RM: Ro52 autoantibodies arise from self-reactive progenitors in a mother of a child with neonatal lupus. *J Autoimmun* 2017; 79: 99-104.
 94. MINGUENEAU M, BOUDAUD S, HASKETT S *et al.*: Cytometry by time-of-flight immunophenotyping identifies a blood Sjögren's signature correlating with disease activity and glandular inflammation. *J Allergy Clin Immunol* 2016; 137: 1809-21 e12.
 95. VAN GINKEL MS, HAACKE EA, BOOTSMA H *et al.*: Presence of intraepithelial B-lymphocytes is associated with the formation of lymphoepithelial lesions in salivary glands of primary Sjögren's syndrome patients. *Clin Exp Rheumatol* 2019; 37 (Suppl. 118): S42-8.
 96. BACON CM, DU MQ, DOGAN A: Mucosa-associated lymphoid tissue (MALT) lymphoma: a practical guide for pathologists. *J Clin Pathol* 2007; 60: 361-72.
 97. EHRHARDT GR, HSU JT, GARTLAND L *et al.*: Expression of the immunoregulatory molecule FcRH4 defines a distinctive tissue-based population of memory B cells. *J Exp Med* 2005; 202: 783-91.
 98. EHRHARDT GR, HIJIKATA A, KITAMURA H, OHARA O, WANG JY, COOPER MD: Discriminating gene expression profiles of memory B cell subpopulations. *J Exp Med* 2008; 205: 1807-17.
 99. LIU Y, GOROSHKO S, LEUNG LYT *et al.*: FCRL4 is an Fc receptor for systemic IgA, but not mucosal secretory IgA. *J Immunol* 2020; 205: 533-8.
 100. SOHN HW, KRUEGER PD, DAVIS RS, PIERCE SK: FcRL4 acts as an adaptive to innate molecular switch dampening BCR signaling and enhancing TLR signaling. *Blood* 2011; 118: 6332-41.
 101. JOURDAN M, ROBERT N, CREN M *et al.*: Characterization of human FCRL4-positive B cells. *PLoS One* 2017; 12: e0179793.
 102. FALINI B, TIACCI E, PUCCIARINI A *et al.*: Expression of the IRTA1 receptor identifies intraepithelial and subepithelial marginal zone B cells of the mucosa-associated lymphoid tissue (MALT). *Blood* 2003; 102: 3684-92.
 103. HAACKE EA, BOOTSMA H, SPIJKERVET FKL *et al.*: FcRL4^{hi} B-cells in salivary glands of primary Sjögren's syndrome patients. *J Autoimmun* 2017; 81: 90-8.
 104. VERSTAPPEN GM, ICE JA, BOOTSMA H *et al.*: Gene expression profiling of epithelium-associated FcRL4^{hi} B cells in primary Sjögren's syndrome reveals a pathogenic signature. *J Autoimmun* 2020; 109: 102439.
 105. VISSER A, VERSTAPPEN GM, VAN DER VEGT B *et al.*: Repertoire analysis of B-cells located in striated ducts of salivary glands of patients with Sjögren's syndrome. *Front Immunol* 2020; 11: 1486.
 106. DORNER T, POSCH MG, LI Y *et al.*: Treatment of primary Sjögren's syndrome with ivalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity. *Ann Rheumatic Dis* 2019; 78: 641-7.
 107. GANDOLFO S, DE VITA S: Double anti-B cell and anti-BAFF targeting for the treatment of primary Sjögren's syndrome. *Clin Exp Rheumatol* 2019; 37 (Suppl. 118): S199-208.
 108. RIP J, VAN DER PLOEG EK, HENDRIKS RW, CORNETH OBJ: The role of Bruton's tyrosine kinase in immune cell signaling and systemic autoimmunity. *Crit Rev Immunol* 2018; 38: 17-62.
 109. GOTTENBERG JE, DORNER T, BOOTSMA H *et al.*: Efficacy of epratuzumab, an anti-CD22 Monoclonal IgG antibody, in systemic lupus erythematosus patients with associated Sjögren's syndrome: post hoc analyses from the EMBODY trials. *Arthritis Rheumatol* 2018; 70: 763-73.
 110. FISHER BA, SZANTO A, NG WF *et al.*: Assessment of the anti-CD40 antibody iscalimab in patients with primary Sjögren's syndrome: a multicentre, randomised, double-blind, placebo-controlled, proof-of-concept study. *Lancet Rheumatol* 2020; 2: E142-E52.
 111. VAN DER HEIJDEN E, BLOKLAND S, HILLEN M *et al.*: Leflunomide-hydroxychloroquine combination therapy in patients with primary Sjögren's syndrome (RepurpSS-I): a placebo-controlled, double-blinded, randomised clinical trial. *Lancet Rheumatol* 2020; 2: E260-E9.
 112. VAN NIMWEGEN JF, MOSSEL E, VAN ZUIDEN GS *et al.*: Abatacept treatment for patients with early active primary Sjögren's syndrome: a single-centre, randomised, double-blind, placebo-controlled, phase 3 trial (ASAP-III study). *Lancet Rheumatol* 2020; 2: E153-E63.

113. VAN VOLLENHOVEN RF, HAHN BH, TSOKOS GC *et al.*: Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study. *Lancet* 2018; 392: 1330-9.
114. MORAND EF, FURIE R, TANAKA Y *et al.*: Trial of Anifrolumab in Active Systemic Lupus Erythematosus. *N Engl J Med* 2020; 382: 211-21.
115. TARN JR, HOWARD-TRIPP N, LENDREM DW *et al.*: Symptom-based stratification of patients with primary Sjögren's syndrome: multi-dimensional characterisation of international observational cohorts and reanalyses of randomised clinical trials. *Lancet Rheumatol* 2019; 1: E85-E94.
116. CHEVALIER K, BELKHIR R, SEROR R, MARIETTE X, NOCTURNE G: Efficacy of a sequential treatment by anti-CD 20 monoclonal antibody and belimumab in type II cryoglobulinaemia associated with primary Sjögren syndrome refractory to rituximab alone. *Ann Rheum Dis* 2020; 79: 1257-9.
117. JEELALL YS, WANG JQ, LAW HD *et al.*: Human lymphoma mutations reveal CARD11 as the switch between self-antigen-induced B cell death or proliferation and autoantibody production. *J Exp Med* 2012; 209: 1907-17.
118. WILSON WH, YOUNG RM, SCHMITZ R *et al.*: Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. *Nat Med* 2015; 21: 922.
119. RATHMELL JC, FOURNIER S, WEINTRAUB BC, ALLISON JP, GOODNOW CC: Repression of B7.2 on self-reactive B cells is essential to prevent proliferation and allow Fas-mediated deletion by CD4⁺ T cells. *J Exp Med* 1998; 188: 651-9.
120. FASANO S, ISENBERG DA: Present and novel biologic drugs in primary Sjögren's syndrome. *Clin Exp Rheumatol* 2019; 37 (Suppl. 118): S167-74.
121. BAER A, GOTTENBERG JE, ST. CLAIR EW *et al.*: Efficacy and safety of Abatacept in active primary Sjögren's syndrome: Results of a randomised placebo-controlled phase III trial. *Ann Rheum Dis* 2019; 78: 89-90.
122. CAFARO G, CROIA C, ARGYROPOULOU OD *et al.*: One year in review 2019: Sjögren's syndrome. *Clin Exp Rheumatol* 2019; 37 (Suppl. 118): S3-15.
123. MEIJER JM, MEINERS PM, VISSINK A *et al.*: Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial. *Arthritis Rheum* 2010; 62:960-8.
124. MOERMAN RV, ARENDS S, MEINERS PM *et al.*: EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) is sensitive to show efficacy of rituximab treatment in a randomised controlled trial. *Ann Rheum Dis* 2014; 73: 472-4.
125. DELLI K, HAACKE EA, KROESE FG *et al.*: Towards personalised treatment in primary Sjögren's syndrome: baseline parotid histopathology predicts responsiveness to rituximab treatment. *Ann Rheum Dis* 2016; 75: 1933-8.
126. DEVAUCHELLE-PENSEC V, MARIETTE X, JOUSSE-JOULIN S *et al.*: Treatment of primary Sjögren syndrome with rituximab: a randomized trial. *Ann Intern Med* 2014; 160: 233-42.
127. CORNEC D, DEVAUCHELLE-PENSEC V, MARIETTE X *et al.*: Development of the Sjögren's Syndrome Responder Index, a data-driven composite endpoint for assessing treatment efficacy. *Rheumatology (Oxford)* 2015; 54: 1699-708.
128. JOUSSE-JOULIN S, DEVAUCHELLE-PENSEC V, CORNEC D *et al.*: Brief report: Ultrasonographic assessment of salivary gland response to rituximab in primary Sjögren's syndrome. *Arthritis Rheum* 2015; 67: 1623-8.
129. BOWMAN SJ, EVERETT CC, O'DWYER JL *et al.*: Randomized controlled trial of rituximab and cost-effectiveness analysis in treating fatigue and oral dryness in primary Sjögren's syndrome. *Arthritis Rheum* 2017; 69: 1440-50.
130. FISHER BA, EVERETT CC, ROUT J *et al.*: Effect of rituximab on a salivary gland ultrasound score in primary Sjögren's syndrome: results of the TRACTISS randomised double-blind multicentre substudy. *Ann Rheum Dis* 2018; 77: 412-6.
131. DÖRNER T, BOWMAN SJ, FOX R *et al.*: OP0302 Ianalumab (VAY736), a dual mode of action biologic combining BAFF receptor inhibition with B cell depletion, reaches primary endpoint for treatment of primary Sjögren's syndrome. *Ann Rheum Dis* 2020; 79 (Suppl. 1): 187-8.